Avoro Capital Advisors 13F: Cuts uniQure (QURE) Stake by $8.8M

Avoro Capital Advisors Trims Stake in uniQure N.V.

Avoro Capital Advisors trimmed its position in uniQure N.V. (NasdaqGS: QURE) during the reporting period, according to a recent Form 13F filing with the Securities and Exchange Commission. The filing reflects holdings as of the reporting period and may not represent the investor's current position.

Details of the Portfolio Adjustment

The fund shed 190,405 shares of the biotechnology developer, marking a 3.1% reduction from its prior holding of 6,150,000 shares. Following the trade, Avoro holds 5,959,595 shares. Based on the data provided, the remaining stake carries a reported value of about $276.7 million.

uniQure Stock Performance and Market Context

uniQure shares trade around $46.42, sitting well above its 52-week low of $8.73 but below its peak of $71.50. The company carries a market capitalization of roughly $1.56 billion. Because the company is not currently profitable, it has no meaningful P/E ratio.

Recent Insider Transactions

Company insiders have been active in the open market recently. On June 26, 2026, Chief Medical Officer Walid Abi-Saab sold 1,434 shares at an average price of $46.86 for a total value of $67,197.24. Chief Executive Officer Matthew Kapusta also engaged in multiple transactions, including a purchase of 4,128 shares on June 24, 2026, at $31.71 per share worth $130,898.88, alongside planned sales and additional open-market purchases.

Analysts Set New Price Targets

Wall Street firms continue to monitor uniQure closely with mixed rating updates. On October 5, 2026, Barclays downgraded the stock to an Equal-Weight rating with a price target of $28.00. Earlier, on October 2, 2026, RBC Capital maintained an Outperform rating with a $48.00 price target. Goldman Sachs maintained a Neutral rating with a $31.00 price target on September 30, 2026.

About uniQure N.V.

Headquartered in Amsterdam, Netherlands, uniQure N.V. develops gene therapies and treatments for rare and devastating illnesses. Its pipeline includes candidates targeting Huntington's disease, epilepsy, and ALS, alongside commercial products like HEMGENIX for hemophilia B. This institutional filing comes as the company advances its clinical trials.

What to Watch at uniQure N.V.

Investors will look toward uniQure's next earnings report, scheduled for November 9, 2026, for updates on its clinical pipeline and financial runway. Institutional 13F filings offer a backward-looking glimpse at portfolio adjustments, meaning these figures may have changed since the reporting date.